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Abstract 
Glioblastoma (GBM) is the commonest primary malignant brain tumour among the adult population. 
Incidence peaks in the 7th and 8th decades of life and as our global population ages, rates are 
increasing. GBM is an almost universally fatal disease with life expectancy in the range of 3-5 months 
amongst the elderly.  
The assessment of elderly GBM patients prior to treatment decisions is poorly researched and 
unstandardized. In order to begin tackling this issue we performed a cross-sectional survey across all 
UK based consultant neuro oncologists to review their current practice in assessing elderly GBM 
patients. 
There were 56 respondents from a total of 93 recipients (60% response rate). All respondents 
confirmed that at least some patients aged 70 or over were referred to their clinics from the local 
multidisciplinary team meeting (MDT). Only 18% of consultants routinely performed a cognitive or 
frailty screening test at initial consultation. Of those who performed a screening test, the majority 
reported that the results of the test changed their treatment decision in approximately 50% of cases. 
Participants ranked performance status as the most important factor in determining treatment 
decisions. 
Considering the heterogeneity of this patient population, we argue that performance status is a 
crude measure of vulnerability within this cohort. Elderly GBM patients represent a unique clinical 
scenario because of the complexity of distinguishing neuro oncology related symptoms from general 
frailty.  There is a need for specific geriatric assessment models tailored to the elderly neuro 
oncology population in order to facilitate treatment decisions.  
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Introduction 
Glioblastoma (GBM) is the commonest primary malignant brain tumour among the adult population 
with approximately 5,000 new cases diagnosed in the UK per year. Incidence peaks in the 7th and 8th 
decades of life and as our global population ages, rates are increasing. Outcomes from this disease 
remain poor with median life expectancy in England at 6.1 months, dropping to 3.2 months amongst 
those aged over 70[1].   
Given the poor prognosis in this group, treatment must be balanced against side effects and 
worsening quality of life. Treatment in those under 65 was standardised by the landmark EORTC 
26981 trial, showing a 2 month survival benefit and a doubling of 2 year survival rates with 
concurrent radiotherapy (RT) and temozolomide (TMZ) chemotherapy followed by 6 months of 
adjuvant TMZ. The age cut off for this trial was 70 and, in the group of trial patients over the age of 
65, the benefit of adding chemotherapy to radiotherapy was not statistically significant[2]. There is 
concern that long course chemotherapy and radiotherapy may in fact be detrimental to elderly and 
frail patients. 
In patients aged 70 or over there is a lack of consensus on standard of care. Radiotherapy has a 
survival advantage over best supportive care[3] however the optimal dose of radiotherapy is yet to 
be established. A recent Phase III trial randomised elderly GBM patients to standard radiotherapy 
with 60Gy in 30#, hypofractionated radiotherapy of 34Gy in 10# or TMZ chemotherapy alone. For 
patients older than 70, survival was significantly longer with TMZ or hypofractionated radiotherapy 
than with standard radiotherapy[4]. Those with defects in the DNA repair protein MGMT did 
significantly better in the chemotherapy arm than those with intact MGMT, a result which was 
replicated in the NOA-08 trial which randomised elderly GBM patients to standard radiotherapy with 
60Gy in 30# or TMZ alone. This non-inferiority trial showed TMZ to be a suitable monotherapy 
option, with greater effect seen in those with MGMT promoter methylation[5]. There is now 
evidence to support the use of chemotherapy or radiotherapy as single agents amongst elderly GBM 
patients and an increasing interest in using MGMT promoter methylation status as a biomarker. 
However there remains a paucity of data surrounding the clinical basis by which individual patients 
are assessed for treatment. 
Assessment of older patients with GBM is challenging due to the mix of tumour-related symptoms 
and pre-existing comorbidities, and it can be difficult to predict which patients will benefit from 
active treatment. Multi-dimensional geriatric assessment has been shown to predict for tolerance to 
treatment and survival in other tumour types[6]. It is apparent that the assessment tools used in 
oncology patients with extra-cranial malignancies are likely to be less valid within the GBM cohort 
because of the unique and potentially isolated deficits caused by the disease itself. As yet there is a 
paucity of trial data assessing the benefit of geriatric assessment in determining treatment options 
and providing a prognostic scoring system amongst elderly neuro oncology patients. In order to 
begin addressing this issue we performed a cross-sectional survey of all UK based consultant neuro-
oncologists, to review their current practice in assessing elderly GBM patients.  
 
 
Materials and methods 
Study design 
A short cross-sectional survey design was used. Data were collected from November to December 
2015. 
Participants 
The survey aimed to capture the views of all currently practising consultant neuro-oncologists in 
England, Scotland, Wales and Northern Ireland.  The participants were identified from conference 
attendances, The Brain Tumour Charity database and direct telephone contact with secretaries 
working at all of the oncology centres within the UK. E-mail addresses were collated and a link to the 
online survey sent to each. 93 participants were identified in total. 
Questionnaire 
The questionnaire was designed by the principal investigator and the validity of the questions 
assessed by 3 consultant co-investigators from 3 different centres. The survey was kept purposefully 
short in order to increase the likelihood of a high response rate. The first section aimed to assess the 
local referral systems for elderly GBM patients to oncology clinics. The second and third sections 
concentrated on how clinicians currently assess elderly GBM patients and how importantly they rank 
certain clinical, pathological and radiological characteristics. The final section assessed local access to 
multidisciplinary team support within the outpatient setting. 
Data collection and analysis 
A link to the online survey was e-mailed to all participating consultant neuro oncologists. 2 
subsequent reminder e-mails were sent. As the survey was anonymised it was not possible to 
identify the non-responders to remind them further. Data was analysed using Microsoft Excel 2010. 
Ethical considerations 
The survey was supported by The Brain Tumour Charity and the NCRI Brain Tumour Clinical Studies 
Group. No financial aid was given. The survey was voluntary, anonymous, aimed only at healthcare 
professionals and therefore was not considered to require IRB approval. 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Responses 
There were 56 responders resulting in an overall response rate of 60%. The survey was anonymised 
so it was not possible to assess the geographical spread of responders.  
Referral to oncology services 
Respondents assessed on a 5 point Likert scale how many patients aged 70 or over discussed at their 
local multidisciplinary meeting were subsequently referred to their oncology outpatient services. All 
participants replied that at least some of those discussed were referred. 20% of participants saw all 
patients aged 70 or over (Table 1). 
Assessment of domains 
Respondents valued performance status as the most important parameter when assessing elderly 
GBM patients for treatment. This was followed by age over 80 and co-morbidities. One respondent 
commented ‘treatment has to be very individualised in glioma patients and cognitive impairment, 
fraility and informed patient choice are the most important factors.’ Despite the publication of the 
NORDIC and NOA-08 trials, there was a marked difference in how responders ranked the importance 
of MGMT methylation status. 6% of responders do not routinely test for MGMT status whereas 48% 
feel that MGMT status is very or extremely important.  The availability of clinical trials was felt to be 
least important (Table 2).  
Cognitive and frailty screening 
80% of respondents do not routinely perform a formal cognitive or frailty screening test on elderly 
GBM patients in clinic. 2% were unsure and of the 18% that do perform a test, the most common is 
the Mini-Mental State Examination. Other tests mentioned include the Montreal Cognitive 
Assessment and the Abbreviated Mental Test Score. 57% of those who do use a test feel it changes 
the decision made at local MDT around half the time.   
Availability of multidisciplinary support 
31% of respondents had access to one or more of physiotherapy, occupational therapy or speech 
and language services during outpatient clinics. 70% of those who had services available felt that 
their assessment rarely changed the initial treatment decision. A number of respondents 
commented on the importance of the clinical nurse specialist in aiding in treatment decisions and to 
‘make the connections’ with other members of the MDT.  
 
 
 
 
 
Discussion 
This is the first study looking at how patients aged 70 and over with GBM are currently assessed 
across UK neuro oncology clinics. There is a growing need to improve outcomes amongst elderly 
oncology patients. Chronological age alone is insufficient to predict for fitness, frailty or tolerance to 
treatment and under treatment is one of a number of reasons why elderly oncology patients do 
worse[7]. We have shown that in a third of UK neuro-oncology MDTs in this survey, only 50% of the 
elderly GBM patients discussed ever meet an oncologist.  
While previous work has suggested that performance status is a blunt tool for detecting the subtle 
and nuanced symptoms that GBM can evoke[8], participants ranked performance status as the most 
important factor in determining treatment decisions. This is consistent with international data. The 
International Society of Geriatric Oncology recommended in 2015 that a geriatric screening 
assessment be performed on elderly oncology patients to assess for referral for a full geriatric 
assessment[9]. As displayed by this survey, in neuro oncology clinics this is yet to occur with 80% of 
respondents not performing a cognitive or frailty test routinely. The reasons for this are likely 
multifactorial including a lack of time and awareness[10] but a key aspect may be the lack of a 
standardised and well validated tool for this cohort. The need for geriatric assessment screening 
tools within neuro oncology is validated by the participants, 50% of whom who felt a screening 
assessment changed their decision making half of the time.  
Perhaps unsurprisingly, the survey displays the national heterogeneity in oncological services in 
terms of referrals from MDTs and availability of physiotherapy, occupational therapy and speech and 
language services. More interesting was the view, from those who did have access, that these 
assessments very rarely changed the initial management decision. It was beyond the scope of this 
survey to assess the potential benefit from early involvement of a multidisciplinary team. 
Despite a handful recent trials focusing on elderly GBM patients, management of this cohort 
continues to prove challenging. Previous reports have identified multiple pre-treatment prognostic 
factors including molecular characteristics (notably MGMT and IDH status), comorbidities, 
neurological status, location of lesion, marital status, language deficit and radiological features. Few 
of these trials were designed specifically for the older cohort of patients.  
Treatment options until recently for elderly GBM patients included palliative short course 
radiotherapy or best supportive care. The results from the NOA-08 and NORDIC trials suggest an 
effective alternative of single agent TMZ amongst those whose tumours show methylation of 
MGMT, reserving radiotherapy (and its attendant toxicity) for subsequent progression. Treatment 
initiation decisions however are still highly subjective.  There remains an urgent need to develop and 
validate a customized neuro-oncology based assessment tool for this vulnerable patient group and 
to determine its prognostic and predictive value in a prospective study. Such a tool could 
incorporate components of the geriatric assessment alongside pathological and radiological markers. 
We are aiming to pilot such an assessment tool in a UK based feasibility study later this year. As 
respondents from our survey commented, ‘assessing how intensive to be is very difficult’ and ‘using 
a frailty or cognitive test result as an essential part of the referral might improve selection of 
patients’ 
 
Tables 
Table 1: What proportion of the patients over the age of 70 who are discussed at your local MDT 
with a new diagnosis of likely GBM are seen in your neuro-oncology clinic? 
 
  Respondents 
None of them 0 
Some of them 8 (14%) 
About half of them 10 (18%) 
Most of them 26 (46%) 
All of them 11 (20%) 
Skipped question 1 (2%) 
 
 
 
Table 2:  When assessing a new patient aged 70 or over with a glioblastoma, how would you rate the 
following parameters in determining the treatment you offer? 
 
 
 
 
 
 
 
 
 
  
Not 
important 
Slightly 
important 
Moderately 
important 
Very 
important 
Extremely 
important 
Not 
available 
Age 70-75 8% 23% 40% 17% 12% 0% 
Age 75-80 0% 10% 33% 38% 19% 0% 
Age > 80 0% 0% 15% 50% 35% 0% 
Performance status 0% 0% 0% 15% 85% 0% 
Co-morbidities 0% 4% 15% 37% 44% 0% 
Family support network 0% 27% 40% 25% 8% 0% 
Extent of surgical resection 2% 17% 54% 19% 8% 0% 
MGMT status (if applicable) 4% 15% 27% 29% 19% 6% 
Availability of clinical trials 17% 19% 23% 21% 14% 6% 
Size of tumour and imaging 
features 0% 12% 30% 42% 16% 0% 
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